Get startedLog in
    Picture of PRF Technologies logo

    PRFX — PRF Technologies News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapSucker Stock
    All News

    Israeli drug delivery firm PainReform's 2025 net loss narrows on reduced R&D expenses

    Picture of PRF Technologies logoPRF Technologies
    27/03/2026 12:09
    Overview

Israel healthcare and energy tech firm's 2025 net loss narrowed sharply from prior year

Company completed DeepSolar and LayerBio acquisitions, expanding into solar analytics and ocular drug delivery

R&D expenses fell sharply due to lower clinical trial costs, general expenses remained stable

Result Drivers

ACQUISITIONS - Expansion into solar analytics and ocular drug delivery through DeepSolar and LayerBio acquisitions drove business transformation

R&D EXPENSES - Lower clinical trial costs reduced R&D expenses, partially offset by new LayerBio activities

COMMERCIAL PROGRESS - DeepSolar advanced from acquisition to early commercial deployment with new customer agreements and product launches

Company press release: ID:nGNX3kJSvr

Key Details


    MetricBeat/MissActualConsensus Estimate
    FY Net Income-$4.80 mln
    

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on PRF Technologies

    See all news